Block Drug Salicylamide Feedback Meeting With FDA Requested
This article was originally published in The Tan Sheet
Executive Summary
Block Drug is asking for input from FDA on the adequacy of pharmacokinetic and clinical data to amend the internal analgesics tentative final monograph and reclassify salicylamide from a Category III to a Category I analgesic adjuvant with aspirin.